Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Status:
Completed
Trial end date:
2021-06-08
Target enrollment:
Participant gender:
Summary
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment
with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute
hepatitis C virus (HCV) infection.
Phase:
Phase 2
Details
Lead Sponsor:
Hannover Medical School
Collaborators:
German Center for Infection Research Gilead Sciences HepNet Study House, German Liverfoundation
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir